PRA Health Sciences, Inc. (NASDAQ:PRAH) Files An 8-K Entry into a Material Definitive Agreement

ME Staff
-
0

PRA Health Sciences, Inc. (NASDAQ:PRAH) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.

On November 10, 2016, PRA Health Sciences, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) by and among the Company, the selling stockholder named therein (the “Selling Stockholder”), and Morgan Stanley & Co. LLC (the “Underwriter”), relating to an underwritten offering (the “Offering”) of 7,500,000 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share, to the Company’s Registration Statement on Form S-3 (File No. 333-209883), filed on March 2, 2016, as supplemented by the prospectus supplement dated November 10, 2016. All of the Shares are being sold by the Selling Stockholder. to the Underwriting Agreement, the Underwriter purchased the Shares at a price of $55.51 per share in a transaction that was completed on November 16, 2016.

The description of the Underwriting Agreement is qualified in its entirety by the terms of such agreement, which is incorporated herein by reference and attached to this report as Exhibit 1.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

See the Exhibit Index immediately following the page hereto, which is incorporated herein by reference.



About PRA Health Sciences, Inc. (NASDAQ:PRAH)

PRA Health Sciences, Inc. is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. The Company’s integrated services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. The Company’s service offerings include Product Registration Services, which includes Phase IIb through III product registration trials and Phase IV trials, inclusive of post-marketing commitments and registries; Strategic Solutions, which provides Embedded Solutions and functional outsourcing services, and Early Development Services, which includes Phase I through Phase IIa clinical trials and bioanalytical laboratory services.

PRA Health Sciences, Inc. (NASDAQ:PRAH) Recent Trading Information

PRA Health Sciences, Inc. (NASDAQ:PRAH) closed its last trading session up +0.62 at 54.49 with 1,068,820 shares trading hands.